Finance |Bitcoin Treasuries Month Share Share this article Copy linkX (Twitter)LinkedInFacebookEmail Finance |Bitcoin Treasuries Month Share Share this article Copy linkX (Twitter)LinkedInFacebookEmail

Japanese Bitcoin Treasury Firms Keep Beating BTC. Tax Policy Makes Outperforming U.S. Peers the Easy Part

Share
Share this article
Copy linkX (Twitter)LinkedInFacebookEmail

Japanese Bitcoin Treasury Firms Keep Beating BTC. Tax Policy Makes Outperforming U.S. Peers the Easy Part

While U.S.-listed bitcoin treasury firms struggle to outperform ETFs, Japan’s harsh crypto tax code sends investors into DAT stocks, making outperformance easy.

By Sam Reynolds|Edited by Cheyenne Ligon
Nov 21, 2025, 4:55 p.m.

Earlier this year, at Hong Kong's Bitcoin Asia, there was a growing sense of frustration with Digital Asset Treasury (DAT) companies and their lagging performance against the asset they fill their coffers with.

STORY CONTINUES BELOW
Don't miss another story.Subscribe to the Crypto Daybook Americas Newsletter today. See all newsletters
Sign me up

“Just buy an ETF,” is how Strive Asset Management CEO Matt Cole put it on stage during a panel at the conference.

But in Japan, this isn't the case. Indeed, DATs listed in Tokyo consistently outperform bitcoin because of the local tax treatment of equities vs. crypto.

Those premiums are not random. They are an expression of Japan’s tax incentives, which punish direct crypto gains but reward equity gains with lower rates and loss offsets.

Crypto profits in Japan are treated as miscellaneous income, lumped with salary and other earnings, and taxed at progressive rates that can reach 55% for the highest earnings.

These gains cannot be offset with losses from other sources and cannot be carried forward. Equity profits sit in an entirely different category. They are taxed separately at about 20%, with loss carryforwards allowed and with far simpler reporting requirements. The difference creates a clear financial incentive: holding bitcoin directly risks a high tax bill, while holding a bitcoin-linked stock keeps any gains inside the lower-tax equity bucket.

Investors who want Bitcoin exposure without the 55% tax bill have little choice but to bid up the shares of companies that hold BTC. American firms operate in a neutral tax environment, so their stocks rarely trade far above their BTC holdings.

At the same time, the Tokyo Stock Exchange and Japan Exchange Group are growing increasingly uneasy with the volatility their own tax regime helped fuel, CoinDesk previously reported, as they have begun warning companies about backdoor listing tactics, tightening audits, and signaling that the DAT model may expose retail investors to risks they do not fully understand.

Similar conversations are happening elsewhere in Asia, with regulators in Hong Kong, India, and Australia reportedly concerned about the structure and are discouraging listed companies from going through with the strategy.

Back in Japan, DAT's might soon be losing their luster as the country's tax authority mulls a change to the tax treatment of crypto.

If this happens, without the tax edge, Tokyo-listed DATs will quickly lose their luster. “Just buy an ETF” may end up being the advice that works in Japan too.

BTC Treasuries Theme Month

More For You

Protocol Research: GoPlus Security

Commissioned byGoPlus

What to know:

  • As of October 2025, GoPlus has generated $4.7M in total revenue across its product lines. The GoPlus App is the primary revenue driver, contributing $2.5M (approx. 53%), followed by the SafeToken Protocol at $1.7M.
  • GoPlus Intelligence's Token Security API averaged 717 million monthly calls year-to-date in 2025 , with a peak of nearly 1 billion calls in February 2025. Total blockchain-level requests, including transaction simulations, averaged an additional 350 million per month.
  • Since its January 2025 launch , the $GPS token has registered over $5B in total spot volume and $10B in derivatives volume in 2025. Monthly spot volume peaked in March 2025 at over $1.1B , while derivatives volume peaked the same month at over $4B.
View Full Report

More For You

Coinbase to Snap Up Solana-Based DEX Vector as Acquisition Spree Continues

The exchange’s latest deal folds Solana-native Vector into its consumer trading arm, extending a rapid M&A streak.

What to know:

  • Coinbase is acquiring Vector, a Solana-based on-chain trading platform, with the team set to integrate into Coinbase’s consumer trading division and its standalone apps slated for shutdown.
  • The deal marks Coinbase’s ninth acquisition of 2025, following earlier buys including Echo for $375 million and Deribit for $2.9 billion.
  • Vector’s addition arrives as Solana DEX volume surpasses $1 trillion this year, reinforcing Coinbase’s ambition to build an “everything exchange” with faster token access and improved execution for traders.
Read full story
Latest Crypto News

HBAR Crashes 11.5% Breaking Below Key Support Levels

Michael Saylor Speaks Out Again as MSCI Concerns Mount

U.S. House Bill Would Allow Federal Taxes in BTC While Aiding U.S. Reserve

Fanatics Enters Prediction Markets via Crypto.com Partnership

Coinbase to Snap Up Solana-Based DEX Vector as Acquisition Spree Continues

BTC Traders Brace for Price Crash to $75K; No Bottom Seen: Research Firm

Top Stories

Bitcoin Bounces Above $84K as Fed's Williams Puts December Rate Cut Back on Table

Coinbase to Snap Up Solana-Based DEX Vector as Acquisition Spree Continues

U.S. House Bill Would Allow Federal Taxes in BTC While Aiding U.S. Reserve

Exactly One Year After Strategy’s All-Time High, the Bitcoin-Linked Slide Intensifies

Crypto Markets Today: Bitcoin, Ether Slide as Liquidity Crisis Fuels Heavy Sell-Off

Yen Slump Is Bullish for BTC and Risk Assets. Or Is It?

Market Opportunity
Bitcoin Logo
Bitcoin Price(BTC)
$89,090.33
$89,090.33$89,090.33
+0.07%
USD
Bitcoin (BTC) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

U.S. President Donald Trump filed a lawsuit against JPMorgan Chase and its CEO Jamie Dimon personally, accusing the institution of deliberate debanking. The politician
Share
Incrypted2026/01/23 15:59
Here’s why Polygon price is at risk of a 25% plunge

Here’s why Polygon price is at risk of a 25% plunge

Polygon price continued its freefall, reaching its lowest level since April 21, as the broader crypto sell-off gained momentum. Polygon (POL) dropped to $0.1915, down 32% from its highest point in May and 74% below its 2024 peak. The crash…
Share
Crypto.news2025/06/19 00:56
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26